James P Kanter

This inventor holds 16 USPTO granted patents and 3 published patent applications, plus 2 CIPO patents and 3 EPO patents, primarily in Pharmaceutical Chemistry. Top assignees: Millennium Pharmaceuticals Limited, Eli Lilly and Company, Millenium Pharmaceuticals, Inc.. Active years: 2003-2017.

IDiyas Innovation Intelligence. (2026). Inventor Profile: James P Kanter. Retrieved from https://idiyas.com/inventor/james-p-kanter

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 16 (Patent Applications = 3)

% Patents Active = 43.8

CIPO Patents = 2

EPO Patents = 3 (Patent Applications = 2)

Average Co-Inventor Count = 4.1

ph-index = 4

Forward Citations = 206(Granted Patents)

Location History:

So. San Francisco, CA (US) (2004)
South San Francisco, CA (US) (2003 - 2013)
San Carlos, CA (US) (2013)
San Ramon, CA (2015)
San Ramon, CA (US) (2009 - 2017)

Company Filing History:

14 out of 855

Millennium Pharmaceuticals Limited

patents

1 out of 4,517

Eli Lilly and Company

patents

1 out of 36

Millenium Pharmaceuticals, Inc.

patents

Years Active: 2003-2017

Loading Chart...

Areas of Expertise:

Factor Xa Inhibitors

Pharmaceutical Salts

Heterocyclic Compounds

Chromanes

Chiral Chromones

Polymorphs

Synthesis Methods

Nitrogenous Compounds

16 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9555023 - Pharmaceutical salts and polymorphs of a factor Xa inhibitor (2017-01-31),

2. 9221758 - Methods of synthesizing pharmaceutical salts of a factor Xa inhibitor (2015-12-29),

3. 9061019 - Pharmaceutical salts and polymorphs of a factor Xa inhibitor (2015-06-23),

4. 8557852 - Methods of using crystalline forms of a salt of a factor Xa inhibitor (2013-10-15),

5. 8536184 - Nitrogenous heterocyclic compounds and process for making nitrogenous heterocyclic compounds and intermediates thereof (2013-09-17),

6. 8524907 - Methods of synthesizing pharmaceutical salts of a factor Xa inhibitor (2013-09-03),

7. RE43098 - Nitrogenous heterocyclic compounds and process for making nitrogenous heterocyclic compounds and intermediates thereof (2012-01-09),

8. 7709640 - Nitrogenous heterocyclic compounds and process for making nitrogenous heterocyclic compounds and intermediates thereof (2010-05-04),

9. 7598276 - Pharmaceutical salts and polymorphs of a factor Xa inhibitor (2009-10-06),

10. 6951937 - Nitrogenous heterocyclic compounds and process for making nitrogenous heterocyclic compounds and intermediates thereof (2005-10-04),

11. 6903227 - Synthesis of 2-acyl substituted chromanes and intermediates thereof (2005-06-07),

12. 6855833 - Methods for producing amino substituted chromanes and intermediates thereof (2005-02-15),

13. 6756403 - Methods for producing chiral chromones, chromanes, amino substituted chromanes and intermediates therefor (2004-06-29),

14. 6720317 - Inhibitors of factor Xa (2004-04-13),

15. 6686368 - Inhibitors of factor Xa (2004-02-03),

Title: The Innovative Contributions of James P. Kanter

Introduction

James P. Kanter is a prominent inventor based in San Ramon, California, known for his significant contributions to the field of pharmaceuticals. With a total of 16 patents to his name, Kanter has made remarkable advancements, particularly in the development of factor Xa inhibitors.

Latest Patents

Kanter's latest patents include innovative formulations and methods related to pharmaceutical salts and polymorphs of a factor Xa inhibitor. One of his notable inventions provides for salts comprising a compound of Formula I and an acid that exhibits activity against mammalian factor Xa. Additionally, he has described novel methods for synthesizing pharmaceutical salts of a factor Xa inhibitor, specifically focusing on a compound of Formula I and its maleate salt.

Career Highlights

Throughout his career, Kanter has worked with esteemed organizations such as Millennium Pharmaceuticals Limited and Millennium Pharmaceuticals, Inc. His work has significantly impacted the pharmaceutical industry, particularly in the development of anticoagulant therapies.

Collaborations

Kanter has collaborated with several professionals in his field, including Robert M. Scarborough and Anjali Pandey. These collaborations have further enhanced his research and development efforts.

Conclusion

James P. Kanter's innovative work in the pharmaceutical sector, particularly in the area of factor Xa inhibitors, showcases his dedication to advancing medical science. His contributions continue to influence the development of effective therapeutic solutions.

Profile summary based on public USPTO records.